- 4d Pharma and The University of Texas MD Anderson Cancer Center Monday announced a strategic collaboration aimed at developing 4D's Live Biotherapeutics in cancer.

The alliance would combine MD Anderson's translational medicine and clinical research capabilities with 4D's expertise in the discovery and development of Live Biotherapeutics. It would initially assess 4D's lead oncology candidate, MRx0518, as a potential treatment for solid tumours.

The Phase I study of MRx0518 due to open shortly would enrol up to 132 patients with metastatic cancer across multiple histologies including, non-small cell lung cancer, renal cell carcinoma, bladder cancer and melanoma, who had failed prior anti-PD-1 therapy.

At 9:51am: [LON:DDDD] 4d Pharma Plc Ord 0.25p share price was +15.4p at 119.25p

Story provided by